Skip to content
Head to head

Zymeworks vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ZYME · VRTX

Updated 7 minutes ago

1-year performance, rebased to 100

ZYME +9.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals trades cheapest on trailing earnings.
ZYMEVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price26.14515.02
Change today-2.68%-1.08%
1-year return+9.7%+22.0%
Market cap$1.81B$130.58B
52-week range21.52 – 31.97412.27 – 568.67
Valuation
P/E (TTM)49.3233.14
P/E percentile, own 5-yr range100th99th
P/B7.006.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.0815.32
Net profit (TTM)$-74.71M$3.88B
Revenue (TTM)$265.97M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+828.7%+11.8%
Gross margin--85.5%
Operating margin16.6%33.1%
Net margin16.3%30.7%
Free cash flow (TTM)$-112.97M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership101.1%96.8%
Insider activity (12mo)31 buy / 4 sell28 buy / 22 sell
Short interest (% of float)8.4%1.9%
Analyst consensus100% buy (13)95% buy / 5% hold (21)
Analyst price target$42 (+60%)$624 (+21%)
StockVane view
StockVane Quant RatingC (60)C (68)
Company
Employees2646,400
Founded20031989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.